Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects;Rola doustnej ba̧dź podskórnej drogi podania małych dawek metotreksatu w redukcji objawów niepoza̧danych ze strony układu pokarmowego

Reumatologia

Volumn 47, Issue 4, 2009, Pages 207-211

  Rutkowska Sak, Lidia ^a   Rell Bakalarska, Maria ^b   Lisowska, Barbara ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b Rheumatology Outpatient Department

Author keywords

Intensity of gastrointestinal side effects; Oral; Subcutaneous methotrexate

Indexed keywords

EID: 70350277477     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bingham SJ, Buch MH, Lindsay S, et al. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003; 42:1009-1010.
2. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35:1117-1125.
3. Nagashima M, Matsuoka T, Saitoh K, et al. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 260-267.
4. Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41: 892-898.
5. Brooks PJ, Spruill WJ, Parish RC, Birchmore DA Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-94.
6. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The antiinflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114:154-163.
7. Braun J, Kaestner P, Flaxenberg P, et al. The clinical efficacy and safety of subcutaneous (s.c.) vs oral application of methotrexate (MTX) with patients with active rheumatoid arthritis (RA) - results of randomized, controlled, double-blind, multi-center study. Ann Rheum Dis 2006; 65 (suppl II): 87.
8. Brandt A. Results of an observational study with parenteral MTX. Medac GmbH Germany 2004.
9. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 423-426.
10. Kramer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50:1370-1382.
11. Braun J, Kästner P, Flaxenberg P, et al; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
12. Wegrzyn J, Adeleine P, Miossec R Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63:1232-1234.
13. Świerkot J, Sokolik R, Gruszecka-Marczyńska K i wsp. Skuteczność leczenia i wystȩpowanie działań niepoza̧danych w trakcie terapii metotreksatem podawanym doustnie i podskórnie chorym na reumatoidalne zapalenie stawów. Reumatologia 2008; 46: 322-329.